Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice.

Heine SJ, Franco-Mahecha OL, Sears KT, Drachenberg CB, van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF.

J Immunol. 2019 Apr 1;202(7):2005-2016. doi: 10.4049/jimmunol.1800985. Epub 2019 Feb 20.

PMID:
30787109
2.

Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial.

Ascough S, Vlachantoni I, Kalyan M, Haijema BJ, Wallin-Weber S, Dijkstra-Tiekstra M, Ahmed MS, van Roosmalen M, Grimaldi R, Zhang Q, Leenhouts K, Openshaw PJ, Chiu C.

Am J Respir Crit Care Med. 2019 Aug 15;200(4):481-492. doi: 10.1164/rccm.201810-1921OC.

3.

A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.

Wang D, Lu J, Yu J, Hou H, Leenhouts K, Van Roosmalen ML, Gu T, Jiang C, Kong W, Wu Y.

Immunol Invest. 2018 May;47(4):403-415. doi: 10.1080/08820139.2018.1439505. Epub 2018 Mar 2.

PMID:
29498560
4.

Systemic and mucosal immune responses elicited by intranasal immunization with a pneumococcal bacterium-like particle-based vaccine displaying pneumolysin mutant Plym2.

Lu J, Hou H, Wang D, Leenhouts K, Roosmalen MLV, Sun T, Gu T, Song Y, Jiang C, Kong W, Wu Y.

Immunol Lett. 2017 Jul;187:41-46. doi: 10.1016/j.imlet.2017.05.003. Epub 2017 May 6.

PMID:
28487097
5.

Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Widjaja I, Wicht O, Luytjes W, Leenhouts K, Rottier PJM, van Kuppeveld FJM, Haijema BJ, de Haan CAM.

J Virol. 2016 Jun 10;90(13):5965-5977. doi: 10.1128/JVI.00235-16. Print 2016 Jul 1.

6.

Biophysical Characterization of the Type III Secretion System Translocator Proteins and the Translocator Proteins Attached to Bacterium-Like Particles.

Chen X, Choudhari SP, Kumar P, Toth RT 4th, Kim JH, Van Roosmalen ML, Leenhouts K, Middaugh CR, Picking WL, Picking WD.

J Pharm Sci. 2015 Dec;104(12):4065-4073. doi: 10.1002/jps.24659. Epub 2015 Sep 30.

PMID:
26422758
7.

Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics.

Widjaja I, Rigter A, Jacobino S, van Kuppeveld FJ, Leenhouts K, Palomo C, Melero JA, Leusen JH, Haijema BJ, Rottier PJ, de Haan CA.

PLoS One. 2015 Jun 24;10(6):e0130829. doi: 10.1371/journal.pone.0130829. eCollection 2015.

8.

Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.

Heine SJ, Franco-Mahecha OL, Chen X, Choudhari S, Blackwelder WC, van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF.

Immunol Cell Biol. 2015 Aug;93(7):641-52. doi: 10.1038/icb.2015.24. Epub 2015 Mar 17.

9.

Biophysical characterization of the type III secretion tip proteins and the tip proteins attached to bacterium-like particles.

Choudhari SP, Chen X, Kim JH, Van Roosmalen ML, Greenwood JC 2nd, Joshi SB, Picking WD, Leenhouts K, Middaugh CR, Picking WL.

J Pharm Sci. 2015 Feb;104(2):424-32. doi: 10.1002/jps.24047. Epub 2014 Jun 10.

10.

Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications.

Visweswaran GR, Leenhouts K, van Roosmalen M, Kok J, Buist G.

Appl Microbiol Biotechnol. 2014 May;98(10):4331-45. doi: 10.1007/s00253-014-5633-7. Epub 2014 Mar 21. Review.

11.

Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.

Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A, Leenhouts K, van Roosmalen ML, van Eden W, Broere F.

Vaccine. 2014 May 19;32(24):2904-10. doi: 10.1016/j.vaccine.2014.02.019. Epub 2014 Mar 2.

12.

Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications.

Van Braeckel-Budimir N, Haijema BJ, Leenhouts K.

Front Immunol. 2013 Sep 17;4:282. doi: 10.3389/fimmu.2013.00282. eCollection 2013.

13.

AcmD, a homolog of the major autolysin AcmA of Lactococcus lactis, binds to the cell wall and contributes to cell separation and autolysis.

Visweswaran GR, Steen A, Leenhouts K, Szeliga M, Ruban B, Hesseling-Meinders A, Dijkstra BW, Kuipers OP, Kok J, Buist G.

PLoS One. 2013 Aug 8;8(8):e72167. doi: 10.1371/journal.pone.0072167. eCollection 2013.

14.

A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.

Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M, Leenhouts K, Rottier PJ, Haijema BJ, de Haan CA.

PLoS One. 2013 Aug 12;8(8):e71072. doi: 10.1371/journal.pone.0071072. eCollection 2013.

15.

An expression system for the efficient incorporation of an expanded set of tryptophan analogues.

Petrović DM, Leenhouts K, van Roosmalen ML, Broos J.

Amino Acids. 2013 May;44(5):1329-36. doi: 10.1007/s00726-013-1467-3. Epub 2013 Feb 13.

PMID:
23404517
16.

Monitoring lysin motif-ligand interactions via tryptophan analog fluorescence spectroscopy.

Petrović DM, Leenhouts K, van Roosmalen ML, Kleinjan F, Broos J.

Anal Biochem. 2012 Sep 15;428(2):111-8. doi: 10.1016/j.ab.2012.06.009. Epub 2012 Jun 17.

PMID:
22713342
17.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
18.

Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice.

Nganou-Makamdop K, van Roosmalen ML, Audouy SA, van Gemert GJ, Leenhouts K, Hermsen CC, Sauerwein RW.

Malar J. 2012 Feb 20;11:50. doi: 10.1186/1475-2875-11-50.

19.

Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.

Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.

Vaccine. 2010 Nov 23;28(50):7963-9. doi: 10.1016/j.vaccine.2010.09.066. Epub 2010 Oct 12.

PMID:
20946860
20.

Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles.

Saluja V, Visser MR, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW.

Eur J Pharm Biopharm. 2010 Nov;76(3):470-4. doi: 10.1016/j.ejpb.2010.08.003. Epub 2010 Aug 16.

PMID:
20719246
21.

Heterologous Processing and Export of the Bacteriocins Pediocin PA-1 and Lactococcin A in Lactococcus Lactis: A Study with Leader Exchange.

Chikindas M, Emond E, Haandrikman AJ, Kok J, Leenhouts K, Pandian S, Venema G, Venema K.

Probiotics Antimicrob Proteins. 2010 Jun;2(2):66-76. doi: 10.1007/s12602-009-9023-x.

PMID:
26781115
22.

Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW.

AAPS J. 2010 Jun;12(2):109-16. doi: 10.1208/s12248-009-9168-2. Epub 2010 Jan 8.

23.

Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection.

Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML, Leenhouts K, Pasetti MF.

Mucosal Immunol. 2010 Mar;3(2):159-71. doi: 10.1038/mi.2009.131. Epub 2009 Nov 18.

24.

Detection and localization of single LysM-peptidoglycan interactions.

Andre G, Leenhouts K, Hols P, Dufrêne YF.

J Bacteriol. 2008 Nov;190(21):7079-86. doi: 10.1128/JB.00519-08. Epub 2008 Aug 29.

25.

Lactococcus lactis as expression host for the biosynthetic incorporation of tryptophan analogues into recombinant proteins.

El Khattabi M, van Roosmalen ML, Jager D, Metselaar H, Permentier H, Leenhouts K, Broos J.

Biochem J. 2008 Jan 1;409(1):193-8.

PMID:
17910535
26.

Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.

Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT.

Am J Pathol. 2007 May;170(5):1725-38.

27.

Development of lactococcal GEM-based pneumococcal vaccines.

Audouy SA, van Selm S, van Roosmalen ML, Post E, Kanninga R, Neef J, Estevão S, Nieuwenhuis EE, Adrian PV, Leenhouts K, Hermans PW.

Vaccine. 2007 Mar 22;25(13):2497-506. Epub 2006 Sep 18.

PMID:
17081660
28.

Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization.

Audouy SA, van Roosmalen ML, Neef J, Kanninga R, Post E, van Deemter M, Metselaar H, van Selm S, Robillard GT, Leenhouts KJ, Hermans PW.

Vaccine. 2006 Jun 29;24(26):5434-41. Epub 2006 Apr 3.

PMID:
16757068
29.

Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations.

Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, Leenhouts K.

Vaccine. 2006 May 1;24(18):3900-8. Epub 2006 Mar 2.

PMID:
16545511
30.

Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.

van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S, Bosma T, Kuipers A, Post E, Steen A, Kok J, Buist G, Kuipers OP, Robillard G, Leenhouts K.

Methods. 2006 Feb;38(2):144-9.

PMID:
16414272
31.

Novel surface display system for proteins on non-genetically modified gram-positive bacteria.

Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML, Steen A, Buist G, Kok J, Kuipers OP, Robillard G, Leenhouts K.

Appl Environ Microbiol. 2006 Jan;72(1):880-9.

32.

Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes.

Rink R, Kuipers A, de Boef E, Leenhouts KJ, Driessen AJ, Moll GN, Kuipers OP.

Biochemistry. 2005 Jun 21;44(24):8873-82.

PMID:
15952794
33.

NisT, the transporter of the lantibiotic nisin, can transport fully modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides.

Kuipers A, de Boef E, Rink R, Fekken S, Kluskens LD, Driessen AJ, Leenhouts K, Kuipers OP, Moll GN.

J Biol Chem. 2004 May 21;279(21):22176-82. Epub 2004 Mar 24.

34.

Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents.

Steen A, Buist G, Leenhouts KJ, El Khattabi M, Grijpstra F, Zomer AL, Venema G, Kuipers OP, Kok J.

J Biol Chem. 2003 Jun 27;278(26):23874-81. Epub 2003 Apr 8.

35.

Active lipoprotein precursors in the Gram-positive eubacterium Lactococcus lactis.

Venema R, Tjalsma H, van Dijl JM, de Jong A, Leenhouts K, Buist G, Venema G.

J Biol Chem. 2003 Apr 25;278(17):14739-46. Epub 2003 Feb 12.

36.

Cre-loxP recombination system for large genome rearrangements in Lactococcus lactis.

Campo N, Daveran-Mingot ML, Leenhouts K, Ritzenthaler P, Le Bourgeois P.

Appl Environ Microbiol. 2002 May;68(5):2359-67.

37.

Anchoring of proteins to lactic acid bacteria.

Leenhouts K, Buist G, Kok J.

Antonie Van Leeuwenhoek. 1999 Jul-Nov;76(1-4):367-76. Review.

PMID:
10532392
38.

Cloning, expression, and chromosomal stabilization of the Propionibacterium shermanii proline iminopeptidase gene (pip) for food-grade application in Lactococcus lactis.

Leenhouts K, Bolhuis A, Boot J, Deutz I, Toonen M, Venema G, Kok J, Ledeboer A.

Appl Environ Microbiol. 1998 Dec;64(12):4736-42.

39.

Construction of a food-grade multiple-copy integration system for Lactococcus lactis.

Leenhouts K, Bolhuis A, Venema G, Kok J.

Appl Microbiol Biotechnol. 1998 Apr;49(4):417-23.

PMID:
9615484
40.
41.

A chloride-inducible acid resistance mechanism in Lactococcus lactis and its regulation.

Sanders JW, Leenhouts K, Burghoorn J, Brands JR, Venema G, Kok J.

Mol Microbiol. 1998 Jan;27(2):299-310.

42.

Rapid and Efficient Purification Method for Small, Hydrophobic, Cationic Bacteriocins: Purification of Lactococcin B and Pediocin PA-1.

Venema K, Chikindas ML, Seegers J, Haandrikman AJ, Leenhouts KJ, Venema G, Kok J.

Appl Environ Microbiol. 1997 Jan;63(1):305-9.

43.

A general system for generating unlabelled gene replacements in bacterial chromosomes.

Leenhouts K, Buist G, Bolhuis A, ten Berge A, Kiel J, Mierau I, Dabrowska M, Venema G, Kok J.

Mol Gen Genet. 1996 Nov 27;253(1-2):217-24.

PMID:
9003306
44.

Prenatal diagnosis of left ventricular aneurysm in the late second trimester: a case report.

Sherman SJ, Leenhouts KH, Utter GO, Litaker M, Lawson P.

Ultrasound Obstet Gynecol. 1996 Jun;7(6):456-7.

45.

Multiple-peptidase mutants of Lactococcus lactis are severely impaired in their ability to grow in milk.

Mierau I, Kunji ER, Leenhouts KJ, Hellendoorn MA, Haandrikman AJ, Poolman B, Konings WN, Venema G, Kok J.

J Bacteriol. 1996 May;178(10):2794-803.

46.

Topology of LcnD, a protein implicated in the transport of bacteriocins from Lactococcus lactis.

Franke CM, Leenhouts KJ, Haandrikman AJ, Kok J, Venema G, Venema K.

J Bacteriol. 1996 Mar;178(6):1766-9.

47.

A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes.

Law J, Buist G, Haandrikman A, Kok J, Venema G, Leenhouts K.

J Bacteriol. 1995 Dec;177(24):7011-8.

48.

Stress response in Lactococcus lactis: cloning, expression analysis, and mutation of the lactococcal superoxide dismutase gene.

Sanders JW, Leenhouts KJ, Haandrikman AJ, Venema G, Kok J.

J Bacteriol. 1995 Sep;177(18):5254-60.

49.
50.

Cloning and molecular analysis of the dihydrofolate reductase gene from Lactococcus lactis.

Leszczyńska K, Bolhuis A, Leenhouts K, Venema G, Cegłowski P.

Appl Environ Microbiol. 1995 Feb;61(2):561-6.

Supplemental Content

Loading ...
Support Center